Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-01
2007-05-01
Kerr, Kathleen M. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S114000, C424S174100
Reexamination Certificate
active
10415878
ABSTRACT:
The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibition of cells. Such combination therapy thus allows one to use lower doses of cytotoxic agents to avoid or reduce their respective toxicity to patients without compromising their growth inhibitory effects. Thus, these combinations can be used for the treatment of an animal, preferably a mammal, that has a cell proliferative disorder, whether the cells have wild-type Rb or are Rb deficient or Rb negative. One such method, directed to treating cell proliferative disorders includes the step of administering a therapeutic effective amount of a cytotoxic agent followed by administering a therapeutic effective amount of a heat shock protein 90 inhibitor. The cytotoxic agent may be a microtubule-affecting agent, topoisomerase II inhibitor, a platinum complex, paclitaxel, or a paclitaxel derivative. The HSP90 inhibitor may be an ansamycin, radicicol or a synthetic compound that binds to the ATP-binding site of HSP90.
REFERENCES:
patent: 6030945 (2000-02-01), Ashkenazi
Lai, L. et al. (2001) Feasibility of producing porcine nuclear transfer embryos by using G2/M-stage fetal fibroblasts as donors.□□Biol. Reprod. vol. 65, pp. 1558-1564.
Jordan, A. et al. (1998) Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.□□Med. Res. Rev. vol. 18, pp. 259-296. Review.
Nguyen, D. M. et al. (1999) Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. J. Thorac. Cardiovasc. Surg. vol. 118, pp. 908-915.
Munster, P. N. (2000) 17- allylamino-17-demethoxygeldanamycin (17-AAG) (17-AAG) inhibits intra-cellular Akt kinase activity in HER2 overexpressing breast cancer lines and enhances the apoptosis induced by cytotoxic agent, vol. 6, 4545s, Abstract No. 394.
Otterson, G. A. et al. (1994) Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. vol. 9, pp. 3375-3378.
Schulte, T. W. et al. (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. vol. 42, pp. 273-279.
Kroep J. R. et al. (Oct. 2000) Complete resection of the caudate lobe of the liver: technique and results. Br. J. Surg. vol. 83, pp. 1069-1076. Review.
Srethapakdi, M. et al. (Jul. 2000) Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. vol. 60, pp. 3940-3946.
Kylie, A. et al. (2002) Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity. Cancer Res. vol. 62, pp. 3356-3360.
Munster, P. N. et al. (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., vol. 7, pp. 2228-2236.
Brambilla et al. (2000) Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. Am. J. Pathol. vol. 156, No. 3, pp. 939-950.
Hurst, S. et al., HSP90 Inhibitors block the mitotic checkpoint and are synergistically toxic with spindle poisons, Clinical Cancer Res. Nov. 1999, vol. 8, p. 3788s, #293.
Kherfellah, D. et al. Effect of the combination of topoisomerase I and topoisomerase II inhibitors on rat glioblastoma cells and drug-resistants. Pharmacol. Experimental Therapeutics. Mar. 1999. vol. 40, p. 109, #724.
Stebbins, C.E., et al. Crystal structure of the HSP-90 Geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. Apr. 1997. vol. 89, pp. 239-250, especially pp. 239-240 and 246-248.
Rosenhagen, M.C., et al. Synergistic inhibition of the Glucocorticoid receptor by padicicol and benzoquinone ansamycins. Biol. Chem. Mar. 2001. vol. 382, pp. 499-504, especially Figures 3 and 5.
Chavany, et al. “p185erbB2Binds to GRP94 in Vivo”, Journal of Biological Chemistry, vol. 271, No. 9 Mar. 1, 1996, pp. 4974-4977.
Schnur, et al. “erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure—Activity Relationships”, J. Med. Chem. 1995, 38, 3813-3820.
Neckers, “Effects of Geldanamycin and Other Naturally Occurring Small Molecule Antagonists of Heat Shock Protein 90 on HER2 Protein Expression”, Breast Disease 11 (2000) 49-59. pp. 49-59.
Polkar, et al., Influence of cisplatin intrastrand crosslinking on the conformation, theremal stability, and energetics of a 20-mer DNA duplex. Proc. Natl. Acad. Sci. USA, vol. 93, pp. 7606-7611, Jul. '996.
Munster Pamela Nathalie
Rosen Neal
Kerr Kathleen M.
Liu Samuel Wei
Marina Larson & Associates LLC
Sloan-Kettering Institute for Cancer Research
LandOfFree
Methods for enhancing the efficacy of cytotoxic agents... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for enhancing the efficacy of cytotoxic agents..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for enhancing the efficacy of cytotoxic agents... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775649